OLD Second National Bank of Aurora Buys 15 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

OLD Second National Bank of Aurora lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,843 shares of the biopharmaceutical company’s stock after acquiring an additional 15 shares during the quarter. OLD Second National Bank of Aurora’s holdings in Regeneron Pharmaceuticals were worth $2,025,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in REGN. Rakuten Securities Inc. lifted its holdings in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $37,000. Truvestments Capital LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $39,000. Finally, Valley Wealth Managers Inc. purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $49,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $687.27 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The stock’s 50-day moving average is $724.48 and its 200 day moving average is $930.31. The company has a market cap of $75.52 billion, a P/E ratio of 17.01, a PEG ratio of 1.59 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Barclays decreased their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Royal Bank of Canada decreased their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Bank of America reaffirmed an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.